ERBB2 and non-small cell lung carcinoma: In HER2-mutant NSCLC patients with locally advanced, recurrent, or metastatic disease, T-DM1 showed an ORR of 38–44%, an mPFS of 2.8–5.0 months, and an mOS of 5.0–8.1 months (Figure 1) [84,85,88].